Breakthrough Synthetic Platelets Developed to Stop Bleeding in Trauma Patients

Researchers develop platelet-like particles that can integrate into the body's clotting pathways to stop hemorrhage, showing promise in trauma care. The synthetic particles have been successfully tested in larger animal models, paving the way for potential clinical implementation.

author-image
Trim Correspondents
New Update
Breakthrough Synthetic Platelets Developed to Stop Bleeding in Trauma Patients

Breakthrough Synthetic Platelets Developed to Stop Bleeding in Trauma Patients

A groundbreaking studypublished in Science Translational Medicine showcases a biomedical engineering innovation that has the potential to revolutionize trauma care and surgical practices. The research team, led by Chapman University's Founding Dean and Professor Andrew Lyon, has developed platelet-like particles (PLPs) that can integrate into the body's clotting pathways to stop hemorrhage.

Why this matters: This breakthrough in synthetic platelet technology has the potential to significantly reduce mortality rates in trauma patients, particularly in prehospital scenarios where timely access to platelet transfusions is often limited. Widespread adoption of this technology could lead to a substantial improvement in healthcare outcomes and save countless lives.

Patients experiencing acute trauma often require platelet transfusions to manage bleeding, but storage constraints restrict their utility in prehospital scenarios. This gap in surgical and traumacare has ledto the development of synthetic PLPs as a potential alternative for promptly addressing uncontrolled bleeding.

The team has engineered PLPs capable of traveling through the bloodstream and homing to the site of tissue damage, where they augment the clotting process and support subsequent wound healing. "This work is a pivotal moment in biomedical engineering, showcasing the practical translational potential of Platelet-Like Particles,"remarked Lyon.

The study involved rigorous testing in larger animal models of traumatic injury and demonstrated that the intervention is extremely well tolerated across a range of models. According to Ashley Brown, corresponding author on the study, "In the mouse and pig models, healing rates were comparable in animals that received platelet transfusions and synthetic platelet transfusions, and both groups fared better than animals that did not receive either transfusion."

One of the study's most significant findings is that these particles can be excreted renally, presenting a breakthrough in elimination pathways associated with injectable, synthetic biomaterials. The remarkable safety profile demonstrated in the study makes it safe and effective in trauma and surgical interventions.

Given the success of the research, the team is pushing forward on a path aimed at eventually seeing clinical implementation of this technology. This remarkable collaborative effort has led to a solution that not only addresses critical clinical needs but also suggests a paradigm shift in treatment modalities.

The study, published on May 10, 2024, in Science Translational Medicine, was a collaborative effort involving 15 authors from multiple universities, including Chapman University alumna Sanika Pandit. The successful testing of the platelet-like particles in larger animal models, combined with their ability to be excreted renally, sets the stage for potential clinical implementation to enhance medical treatments and outcomes for patients undergoing trauma and surgical procedures.